Longeveron Logo.jpg
Longeveron to Present at Biotech Showcase 2025
18. Dezember 2024 09:10 ET | Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Longeveron Logo.jpg
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
02. Dezember 2024 09:05 ET | Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Wa'el Hashad
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET | Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Longeveron Logo.jpg
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
11. November 2024 09:05 ET | Longeveron
Longeveron has appointed Devin Blass as Chief Technology Officer (CTO) and SVP of CMC, effective Dec 2, adding capabilities ahead of potential BLA filing.
Longeveron Logo.jpg
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
04. November 2024 16:05 ET | Longeveron
Longveron will report third quarter 2024 financial results and provide a business update on Tuesday, November 12th after the U.S. financial markets close.
Joshua Hare
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29. Oktober 2024 10:00 ET | Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Joshua Hare
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
27. Oktober 2024 15:10 ET | Longeveron
Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
Wa'el Hashad
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
14. Oktober 2024 09:05 ET | Longeveron
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Wa'el Hashad
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
09. Oktober 2024 09:05 ET | Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
Longeveron Logo.jpg
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
07. Oktober 2024 09:05 ET | Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th